Despite bruising market, two biotechs price their IPOs while another launches its Nasdaq bid
The current market situation for biotechs is certainly not ideal, but that is not deterring a few companies from diving into the waters of Wall Street.
Two companies, Boston-based HilleVax and San Diego-based Belite Bio, will make their Nasdaq debuts Friday, while another biotech that has some familiar names attached filed for an IPO.
After filing earlier this month HilleVax grabs more than $150M
HilleVax, a norovirus vaccine developer spun out from Takeda by late biotech legend Tachi Yamada, went public on the back of a $150 million-plus debut and priced its IPO at $17 per share.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.